US pharmaceutical company Pfizer reported a 6% third-quarter profit increase from last year, due largely to Covid-19 booster vaccine development with German partner BioNTech. Total revenues for the quarter declined 6% to $22.64 billion from $24.04 billion. Still, the net profit increased to $8.61 billion or $1.51 per share from last year’s $8.15 billion or $1.42 per share. Both adjusted earnings and quarterly revenues topped analysts’ expectations. In light of this, the New-York-based company also raised its adjusted earnings and revenue expectations for the full year of 2022. “Third-quarter r…